LEE011 + Letrozole + Tamoxifen + Fulvestrant + goserelin
Phase 1Completed 0 watching 0 views this weekπ€ Quiet
33
Development Stage
β
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
Conditions
Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
Trial Timeline
Feb 4, 2015 β Sep 29, 2022
NCT ID
NCT02333370About LEE011 + Letrozole + Tamoxifen + Fulvestrant + goserelin
LEE011 + Letrozole + Tamoxifen + Fulvestrant + goserelin is a phase 1 stage product being developed by Novartis for Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02333370. Target conditions include Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02333370 | Phase 1 | Completed |
Competing Products
20 competing products in Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer